Analyst Price Target is $235.50
▲ +33.28% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $235.50, with a high forecast of $238.00 and a low forecast of $233.00. The average price target represents a 33.28% upside from the last price of $176.69.
Current Consensus is
The current consensus among 3 polled investment analysts is to hold stock in Medpace. This rating has held steady since July 2022, when it changed from a Buy consensus rating.
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.